Biogen Idec and Multiple Sclerosis
Committed to improving the lives of people with MS
We will.

Sha Mi,
PhD, Principal Investigator,
Department of Discovery Neurobiology
How does a person say

thank you,

for the AVONEX, the TYSABRI,

for all the years of research,

for caring?

Words do not exist, not in any language!

But the gratitude

I can feel with every beat of my heart,

and with every step I take,

and every accomplishment

of my daily living

that I

so appreciate.

Judith Rahmani,
Plainview, NY
Olga Bobrownikova, concert pianist, living her life to the fullest with the help of Biogen Idec.
As the leader in MS
We will continue to offer the greatest hope for patients.

People living with MS inspire us every day. Their courage fuels our efforts to use science and support services to advance the research, treatment and care for people with MS. From scientists discovering potential therapeutic candidates, to customer service specialists offering help to hundreds of patients each week, to our manufacturing associates who make it possible to deliver our products to patients in need – the battle against MS is part of all of us at Biogen Idec.

Today, Biogen Idec offers a continuum of care for people with MS with AVONEX® (interferon beta-1a) and TYSABRI® (natalizumab) and we are aggressively investing in future treatment options with the most diverse and active pipeline in the industry. In addition to our leading research and development efforts, we offer comprehensive patient support services and educational programs designed to attract students to the world of science and biotechnology.
We will provide unparalleled support for our patients.
Commitment to our patients is at the center of everything we do. Our support programs help patients on a daily basis -- from getting started on their therapy to navigating reimbursement issues to providing access to medicines. Biogen Idec understands the power of ‘community’ and its importance to those with MS. Working with physicians, nurses and other healthcare professionals, we work tirelessly to educate the MS community at large and to empower those living with the disease and their caregivers.

Among our programs:

- Dedicated customer care call center
- Nurse support: Nurses visits offered to patients for home injection training and one-on-one assistance.
- "Living Well with MS" seminar series: Nationwide educational programs led by local physicians, nurses and health professionals.
- “MS ActiveSource” website (www.MSActiveSource.com): Comprehensive online MS resource providing access to information, education and other people living with the disease.
- Mentoring program: Teams a ‘veteran’ MS patient with a newly diagnosed patient.
- Community advocacy: Long-standing, passionate commitment to national and regional advocacy groups, patient support and charitable organizations.

Annually: 500,000 calls handled by our customer care center. $85M in free or discounted medicines for patients in need.
We will be unrelenting in the pursuit of breakthrough research.

“We want to extend our expertise in MS research and development to expand into other areas of neurology such as Parkinson’s disease, Alzheimer’s disease, neuropathic pain and other conditions with high unmet need for new treatment options.”

Alfred Sandrock, MD, PhD, Neurologist & Senior Vice President, Neurology R&D
The most robust MS pipeline in the industry

Biogen Idec | Leading Global MS Research

For more information about our portfolio, please visit www.biogenidec.com
Our marketed products and those in development are thought to target different pathways:

- **AVONEX** - Beta interferon that modulates the immune system
- **TYSABRI** - Antibody to alpha-4 integrin that inhibit immune cells from crossing the blood brain barrier
- **BG-12** - An oral immunomodulator with a combination of cytoprotective and anti-inflammatory properties
- **RITUXAN** - Antibody to CD20 that marks mature B-cells for destruction
- **Daclizumab** - Antibody to IL-2 receptor (alpha subunit) that is thought to block the activation of T-cells along with other potential effects
- **CDP 323** - Oral small molecule that targets alpha-4 integrin
- **anti-LINGO-1** - Antibody to the LINGO pathway may allow for remyelination
- **NgR-Fc** - Targeting the Nogo receptor pathway may allow for the regeneration of nerve fibers
Can we reverse the damage inflicted by MS?

One of the programs we are particularly excited about is LINGO-1, which has an important role in regulating myelin formation around nerve fibers. MS is a chronic disease of the CNS in which the body’s own immune cells break down myelin, a fatty substance that typically surrounds nerve cells like the insulation around a wire. Without myelin, nerve fibers lose the ability to properly conduct electrical impulses and may even die. Current MS therapies can slow the progression of the disease, but none are able to repair the damage that the immune system inflicts on myelin. Although the cells that typically wrap nerves with myelin are present in MS patients, they fail to restore the missing myelin sheath following an immune system attack.

A team of Biogen Idec scientists discovered that LINGO-1 appears to be a molecular switch that controls the ability of these CNS cells to myelinate. The team discovered that LINGO-1 normally acts to prevent myelination and that the normal function of LINGO-1 could be blocked in laboratory tissue culture and animal models. In experiments, researchers were able to induce cells to generate large quantities of myelin by blocking LINGO-1 and, for the first time ever in a laboratory setting, to wrap it correctly around nerves.
"The beauty of anti-LINGO-1 is that it appears to promote axon regeneration as well as myelin repair. This suggests that it may have the potential to actually reverse some of the damage inflicted in the CNS by diseases like MS. It is truly exciting to work on a program that has such promise for people with MS."
Nearly **30 percent** of our revenues are devoted to research & development.*

Scientific discovery is at the core of Biogen Idec.

Over the next five years, we expect to spend approximately $5 billion on research and development, much of which will be dedicated to MS. We have dedicated scientists working on MS discoveries and we are collaborating with companies, academic institutions, leading clinical investigators and other partners on therapeutics and technologies.

MS is a lifelong disease that affects each person differently. Our goal is to offer people living with MS a portfolio of therapeutic options so that individuals are treated with the right medicine for the right stage of disease. We are targeting multiple scientific pathways and diverse delivery approaches that offer choice and convenience for patients. We are investigating T-cell and B-cell directed therapies, oral options and are excited about early-stage research programs tackling the next advancement for people living with MS – nerve regeneration and remyelination.

“At Biogen Idec, we are dedicated to the pursuit of creative science and are aggressively seeking new and exciting opportunities in MS research. We are inspired each day to use discovery and development to provide meaningful therapeutic advancements for people living with this debilitating disease. We hope that within ten years, our research brings us to the doorstep of actually reversing some of the damage inflicted by MS and dramatically improving the way people live with the disease.”

*Based on average R&D investment from 2004-2006*
We will transform today’s young students into the discoverers of tomorrow.

“Working in the Community Lab made me realize how much I enjoyed science. I have decided to pursue biology based on my experience at Biogen. It helped me become more aware of how a scientist works and I can see myself doing this type of work.”

Laura, Biogen Idec Community Lab student
In 2006, more than 2,260 students, 180 teachers and 150 Biogen Idec volunteers participated in our Community Labs.

“Our schools cannot shoulder the responsibility of science education alone – they need the active help of not only parents and teachers, but also the business and science communities. Biotechnology, as an industry that employs thousands of scientists, is uniquely positioned to help.”

James C. Mullen, Biogen Idec President & CEO

As a leader in our industry, we recognize there will be enormous demand for talent in the years to come, as well as significant career opportunities in science and medicine. The future success of our industry and our society is dependent on not only R&D pipelines, but the human pipeline of talented and creative young scientists.

The Biogen Idec Community Lab, our onsite teaching facility, and the Biogen Idec Foundation are both focused on enhancing the quality of science education. The Community Labs at our offices in Cambridge, MA and San Diego, CA engage young people in the world of science. Students and teachers visit the lab, team up with our scientists, conduct hands-on experiments and learn about the promise of the biotechnology industry.

The Foundation’s primary focus is to encourage young men and women of all backgrounds to enter scientific careers. Two examples of programs the Foundation supports are: The Biomedical Science Careers Program serves academically outstanding minority students in the Boston area who are pursuing careers in the biomedical and biotechnology field; The Elementary Institute of Science (EIS) has inspired children in the San Diego area for more than four decades, engaging students in hands-on science, health and technology programs.
Over 25 Years of MS research, discovery, and care

1978
Biogen founded

1981
Biogen begins work on beta interferon

1987
Dr. Larry Jacobs of Buffalo General Hospital leads the development of a study of beta interferon in MS

1989
Biogen scientists discover VCAM-1 – the cell surface ligand for alpha-4beta-1 integrin, a key pathway for MS development

1990
A Phase III study of beta interferon in MS begins, led by Dr. Larry Jacobs

1994
Biogen reports positive Phase III results for Interferon beta-1a in MS

1996
AVONEX (Interferon beta-1a) is approved by the US Food and Drug Administration (FDA) for treatment of relapsing forms of MS.

1997
AVONEX is approved by European regulatory authorities

2000
Biogen and Elan Corporation, plc announce a collaboration on the development and commercialization of natalizumab in Phase II for MS and Crohn’s disease

2002
AVONEX becomes the first MS treatment approved in Europe for patients who have their first clinical MS attack and have a brain MRI scan consistent with MS. In 2003, it is approved for this indication in the US.

2003
Phase II study results of natalizumab in MS and Crohn’s disease are published in New England Journal of Medicine

Biogen partners with and later acquires FUMAPHARM AG on the development of BG-12, an oral fumarate in autoimmune diseases, including MS

AVONEX prefilled syringe is launched
Biogen and IDEC Pharmaceuticals merge

2004

TYSABRI (natalizumab) receives Accelerated Approval by the FDA for treatment of relapsing forms of MS

2005

Biogen Idec and Elan voluntarily suspend TYSABRI from the market after reports of progressive multifocal leukoencephalopathy (PML) and launch extensive safety evaluation of the product

Biogen Idec and Protein Design Labs collaborate on several monoclonal antibodies, including MS candidate daclizumab

Research published in *Nature Neuroscience* is the first to suggest a role for anti-LINGO-1 in nerve repair, and could lead to potential pathways for treating MS and other demyelinating diseases

2006

Two-year data and safety evaluation of TYSABRI published in *New England Journal of Medicine*

After a public FDA Advisory Committee meeting and FDA review, TYSABRI returns to market under the TOUCH™ Prescribing Program

TYSABRI is approved by the European Commission

Phase II study of RITUXAN in relapsing-remitting MS achieves primary endpoint

Positive Phase II results of BG-12 in MS presented at two European neurological meetings

Biogen Idec and UCB Pharma enter collaboration on CDP 323, an oral MS candidate

AVONEX, the most prescribed MS therapy, marks 10-year anniversary in US

AVONEX approved and introduced in Japan

2007

Biogen Idec initiates BG-12 Phase III program

For more information, please visit www.biogenidec.com
Biogen Idec Worldwide Operations
Extending our Global Reach

**Corporate Headquarters**
Biogen Idec Inc.
14 Cambridge Center
Cambridge, MA 02142
United States
Telephone: (617) 679 2000

**International Headquarters**
Biogen Idec International GmbH
Landis & Gyr-Strasse 3
CH-6300 Zug
Switzerland
Phone: +41 41 39 21700
www.biogenidec.ch

**Belgium**
Biogen Idec International S.A./N.V.
Regus Pegasus
Pegasuslaan 5
1831 DIEGEM
Phone: +11 32 2 219 12 18
www.biogenidec.be

**Brazil**
Biogen Idec Brazil
Av. Pres. J. Kubitschek 1400
cj 61, cep 04543-000
Sao Paulo, Sp

**Canada**
Biogen Idec Canada Inc
3 Robert Speck Parkway
Suite 300
Mississauga, Ontario L4Z 2G5
Phone: +1 905 804 1444

**China**
Biogen Idec China
Unit 07B-09, Level 41
Plaza 66
1266, Nanjing Xi Lu
Shanghai
200040

**Czech Republic**
Biogen Idec (Czech Republic) s.r.o.
Na Strzi 65
140 00 Praha 4
Phone: +420 222 191 640

**Denmark**
Biogen Idec Denmark A/S
Orestads Boulevard 67
2300 Copenhagen S
Phone: +45 7741 5757
Biogen Idec Manufacturing Aps
Biogen Idec Alle 1
3400 Hillerød
Phone: +45 7741 6000
www.biogenidec.dk

**Finland**
Biogen Idec Finland OY
Ayratie 12C
SF-01510 Vantaa
Phone: +358 207 401 200
www.biogenidec.fi

**France**
Biogen Idec France SAS
“Le Capitole”
55 Avenue des Champs Pierreux
92012 Nanterre Cedex
Phone: +33 1 41 37 95 95
www.biogenidec.fr

**Germany**
Biogen Idec GmbH
Carl-Zeiss Ring 6
85737 Ismaning
Phone: +49 89 99 61 70
www.biogenidec.de

**India**
Biogen Idec Biotech India Pvt. Ltd
Vatika Towers,
Tower - B, 14th Floor,
Sector - 54,
Golf Course Sector Road,
Gurgaon - 122 002
Ireland
Biogen Idec (Ireland) Ltd
United Drug House
Magna Business House
Magna Drive, City Rd
Dublin 24
Phone: +353 1 463 7725

Italy
Biogen Dompé S.r.l.
Via San Martino 12-12/A
20122 Milano
Phone: +39 02 58 38 31
www.dompe.it

Japan
Biogen Idec Japan Ltd.
Atago Green Hills Mori Tower 26F
5-1, Atago 2-chome
Minato-ku
Tokyo 105-6226
Phone: +81 3 6402 7800
www.biogenidec.co.jp

The Netherlands
Biogen Idec International BV
Tokyostraat 31-33
1175 RB Lijnden
The Netherlands
Tel: +31 20 542 2022
www.biogenidec.nl

New Zealand
Biogen Idec New Zealand
54 Carbine Road
PO Box 62-027
Mt. Wellington
1641 Auckland
Phone: +64 9 915 9661

Norway
Biogen Idec Norway AS
Karenlyst Allé 8B
Skøyen, 0278 Oslo
Phone: +47 23 12 06 38/39
www.biogenidec.no

Portugal
Biogen Idec Portugal
Avenida Duque d’Alva, 185,Floor 8
1050-082 Lisboa
Phone: +35 1 21 318 84 50

Slovak Republic
Biogen Idec (Slovak Republic) s.r.o
Palisady 33
81106 Bratislava
Phone: +421 2 3241 0188

Slovenia
Biogen Idec Austria GmbH
Represent. Office Slovenia
Masera Spasiceva 10
1000 Ljubljana
Phone: +386 1 589 91 04

Spain
Biogen Idec Iberia, S.L.
Paseo de la Castellana 41 - 3a
28046 Madrid
Phone: +34 91 310 71 10
www.biogenidec.es

Sweden
Biogen Idec Sweden AB
Kanalvägen 1A,Plan 2
19461 Upplands Väsby
Phone: +46 8 594 113 60

United Kingdom
Biogen Idec Limited
Thames House, Foundation Park
Maidenhead
Berkshire SL6 3UD
Phone: +44 1628 501000

United States | North Carolina
Biogen Idec
5000 Davis Drive
Research Triangle Park, NC 27709
(919) 993-1100

United States | California
Biogen Idec
5200 Research Place
San Diego, CA 92122
(858) 401-8000
People living with MS inspire us everyday with their courage and unyielding drive to live life to the fullest.
The support of many allows us to pursue our passion to offer new hope for MS patients.

We recognize all neurologists who demonstrate unwavering dedication to bettering the lives of MS patients with sincere support and the best medical care possible.

We appreciate all Biogen Idec employees, who strive to bring the best products and support services to patients and tenaciously pursue breakthrough research with the goal of improving the lives of all people with MS.

We acknowledge all people who volunteer countless hours for the greater MS community, encouraging charitable donations, driving essential MS awareness and education and pursue critical exploratory research.

The collective support of neurologists, patients, and the greater MS Community enable us to dedicate our lives to breakthrough discoveries and offering hope to all people living with MS.


Biogen Idec (NASDAQ: BIIB) creates novel approaches in therapeutic areas with high unmet medical needs. Founded in 1978, Biogen Idec is a global leader in the discovery, development, manufacturing, and commercialization of innovative therapies. Patients in more than 90 countries benefit from Biogen Idec’s significant products that address diseases such as lymphoma, multiple sclerosis, and rheumatoid arthritis.

Safe Harbor / Forward-Looking Statements:
This brochure contains forward-looking statements regarding expected future financial results, the size and growth of the markets for our products, and plans for our product development programs. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those that we expect. Important factors that could cause our actual results to differ include the uncertainty of success in commercializing our products, including the launch of TYSABRI, the occurrence of adverse safety events with our products, our dependence on collaborations over which we may not always have full control, possible adverse impact of government regulation and changes in the availability of reimbursement for our products, problems with our manufacturing processes and our reliance on third parties, our ability to protect our intellectual property rights and the cost of doing so, the risks of doing business internationally and the other risks and uncertainties that are described in our filings with the Securities and Exchange Commission, including our Annual Report on Form 10-K filed in February, 2007. These forward-looking statements speak only as of the date of this brochure, and we do not undertake any obligation to publicly update any forward-looking statements, whether as a result of new information, future events, or otherwise. All of the Company’s SEC filings are available at the SEC’s website, www.sec.gov, or upon request from the Company’s Investor Relations Department (617.679.2812).

BIOGEN IDEC, and the BIOGEN IDEC logo are trademarks of Biogen Idec. AVONEX® and RITUXAN® are registered trademarks of Biogen Idec. TYSABRI® is a registered trademark and TOUCH™ is a trademark of Elan Pharmaceuticals.
We will never give up.

Want to know more?
For more information on Biogen Idec and multiple sclerosis, please visit www.biogenidec.com or contact:
Investor Relations
1. 617. 679. 2812
Public Affairs
1. 617. 914. 6524

© Biogen Idec 2007